PLYMOUTH
MEETING, Pa., Jan. 3, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or
the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated
to developing and commercializing innovative therapies for patients
with rare neurological diseases, today announced its participation
in the 42nd Annual J.P. Morgan Healthcare Conference in
San Francisco, CA. Jeffrey M. Dayno, M.D., President and Chief Executive Officer of
Harmony, is scheduled to present at the conference on Wednesday, January 10, 2024, at 5:15 p.m. PT/8:15 p.m.
ET.
A live webcast of the presentation will be available on the
investor page of Harmony's website at
https://ir.harmonybiosciences.com/.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and
delivering treatments for rare neurological diseases that others
often overlook. We believe that where empathy and innovation meet,
a better life can begin for people living with neurological
diseases. Established by Paragon Biosciences, LLC, in 2017 and
headquartered in Plymouth Meeting,
PA, our team of experts from a wide variety of disciplines
and experiences is driven by our shared conviction that innovative
science translates into therapeutic possibilities for our patients,
who are at the heart of everything we do. For more information,
please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024886.html
SOURCE Harmony Biosciences